Healthcare professional with mask holding up a digital screen.

AstraZeneca made a commitment to deliver plain language summaries (PLS) in advance of the European Medicines Agency (EMA) policy. Partnering with Citeline, AstraZeneca decided its results would be available on

The hard part was the resistance from trial sites on distribution of PLS.
Julie Holtzople, Clinical Trial Transparency Operations Director, AstraZeneca

Related resources

Trial Summaries-Improving Patient-Centric Communications resource-card-thumbnail
JUL 01, 2023
White paper
Regulatory & Compliance

Trial Summaries Improving Patient-Centric Communications

The Pharma R&D Annual Review 2023 Supplement looks at new active substances (NASs), drugs launched onto the market for the first time, during 2022

SEP 01, 2023
White paper
Regulatory & Compliance

Clinical Trial Disclosure Compliance a Moving Target Due to Ever-changing Global Regulations

Gain insights on key factors driving disclosure rule updates and ways to minimize noncompliance risks.

EU transparency img-resource-card-thumbnail
MAY 01, 2022
Regulatory & Compliance

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency